Axa S.A. Freeline Therapeutics Holdings PLC Transaction History

Axa S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$0.92 - $2.03 $261,114 - $576,154	-283,820 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.97 - $3.45 $556,302 - $974,235	-282,387 Reduced 49.87%	283,820 $562,000
Q3 2021 Nov 15, 2021	BUY	$3.04 - $8.9 $31,774 - $93,022	10,452 Added 1.88%	566,207 $1.93 Million
Q2 2021 Aug 13, 2021	SELL	$8.15 - $13.9 $187 - $319	-23 Reduced -0.0%	555,755 $4.53 Million
Q1 2021 May 14, 2021	BUY	$12.3 - $18.2 $52,914 - $78,296	4,302 Added 0.78%	555,778 $6.84 Million
Q4 2020 Feb 12, 2021	BUY	$14.94 - $18.3 $34,690 - $42,492	2,322 Added 0.42%	551,476 $10.1 Million
Q3 2020 Nov 13, 2020	BUY	$15.45 - $18.12 $8.48 Million - $9.95 Million	549,154 New	549,154 $8.57 Million

30.1K

Ticker FRLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,972,300
Description
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.